The KANK2 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human non-small cell lung adenocarcinoma cell line NCI-H1975. This product consists of a heterogeneous pool of cells with disrupted KANK2 gene sequences, enabling loss-of-function studies in a lung cancer context. The polyclonal format provides a representative model of gene disruption without clonal selection, suitable for experiments requiring population-level analysis. It is designed to facilitate investigation of KANK2??s role in actin cytoskeleton regulation, focal adhesion dynamics, and cell migration.
The parental NCI-H1975 line originates from a female non-smoker with lung adenocarcinoma and carries the EGFR L858R and T790M mutations, conferring constitutive kinase activity and resistance to first-generation EGFR inhibitors. This cell line is a well-established model for studying acquired drug resistance, invasion, and signaling in EGFR-mutant NSCLC. Its inherent alteration of migratory and adhesive properties makes it an appropriate host for exploring the impact of KANK2 loss on these processes.
KANK2 functions as a scaffold protein that binds talin at focal adhesions and recruits liprin-beta, forming a complex that negatively regulates RhoA GTPase. This inhibition suppresses ROCK activity, reducing phosphorylation of myosin light chain and cofilin to modulate actin polymerization and contractility. Upstream signals from integrin ligation and actin polymerization activate KANK2, whereas its downstream effects control focal adhesion turnover and cell migration. Thus, KANK2 acts as a key node linking integrin adhesion to RhoA/ROCK-mediated cytoskeletal reorganization.
In the EGFR-mutant NCI-H1975 background, knockout of KANK2 may disrupt the normal inhibition of RhoA, leading to increased ROCK signaling and altered focal adhesion dynamics. This could affect cell motility, invasion, and potentially drug sensitivity, providing a platform to investigate the interplay between oncogenic EGFR and adhesion-dependent signaling. Studying KANK2 deficiency in this model may help uncover mechanisms of metastasis and therapeutic resistance in NSCLC.
Applications include western blotting and immunofluorescence to verify target knockout and assess focal adhesion protein distribution, as well as migration and invasion assays to quantify cell motility. Co-immunoprecipitation can probe protein interaction changes, while RhoA activity assays measure downstream signaling. The cells are also suitable for cell adhesion assays and transcriptomic analyses. For additional information or technical inquiries, please contact Ascent Research.
